Application of Thonningianin A to preparation of drug for preventing or treating alcoholic cardiomyopathy

Abstract

The invention discloses the application of Thonningianin A to the preparation of A drug for preventing or treating alcoholic cardiomyopathy. The Thonningianin A (TA) provided by the invention significantly reduces the plasma CK-MB content in an alcoholic cardiomyopathy model, and the reduction by high dose of TA is 38.12%, thereby restoring cardiac ejection ability and alleviating cardiac hypertrophy in alcoholic cardiomyopathy, and significantly reducing myocardial damage caused by the alcoholic cardiomyopathy model. At present, the clinical manifestations of the alcoholic cardiomyopathy areoften accompanied by cardiac dilatation and congestive heart-failure, especially left ventricular failure prevails. TA can effectively restore the increased left ventricular posterior wall thickness and myocardial damage, so TA effectively alleviates the cardiac trauma caused by an alcohol diet model.

Description

(1) Technical field [0001] The present invention relates to a new application of Thonningianin A (TA), that is, the application of Thonningianin A in the preparation of drugs for preventing or treating alcoholic cardiomyopathy. (2) Background technology [0002] Alcohol cardiomyopathy (alcoholic cardiomyopathy, ACM) is a growing disease in the cardiovascular field, a secondary heart disease caused by long-term alcohol consumption leading to myocardial degeneration, heart enlargement and heart failure. Alcohol abuse is the leading cause of nonischemic cardiomyopathy in the United States, accounting for approximately 3.8% of all cardiomyopathy. Chronic alcohol intake has been reported to be a major cause of congestive heart failure due to dilated cardiomyopathy, a form of congestive heart failure that accounts for approximately 35% of cases of nonischemic dilated cardiomyopathy. At present, the pathogenesis of alcoholic cardiomyopathy is not yet clear. Studies have shown that...

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of alcoholic cardiomyopathy is not yet clear. Studies have shown that a large amount of alcohol can cause the loss of left ventricular cardiomyocytes, which in turn can cause cardiac insufficiency, mitochondrial damage, calcium homeostasis imbalance, changes in myocardial contractile proteins, etc.

Images